SCNI Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Valuation Metrics

The current forward P/E ratio for Scinai Immunotherapeutics Ltd (SCNI.O) is 0.00, compared to its 5-year average forward P/E of -5.38. For a more detailed relative valuation and DCF analysis to assess Scinai Immunotherapeutics Ltd 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-5.38

Current PE

0.00

Overvalued PE

6.99

Undervalued PE

-17.76

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

SCNI News & Events

Events Timeline

No data

News

1.0

01-07PRnewswire

Scinai CEO to Co-Lead Biopharma Roundtable at HealthIL Week 2026

1.0

01-07Newsfilter

Scinai CEO to Co-Lead Biopharma Roundtable at HealthIL Week 2026

9.0

2025-07-29Newsfilter

Scinai Announces New Peer-Reviewed Publication Supporting PC111 as a Disease-Modifying Therapy for Pemphigus and SJS/TEN

People Also Watch

Frequently Asked Questions

What is Scinai Immunotherapeutics Ltd (SCNI) stock price today?

The current price of SCNI is 0.762 USD — it has decreased -5.34 % in the last trading day.

What is Scinai Immunotherapeutics Ltd (SCNI)'s business?

Scinai Immunotherapeutics Ltd, formerly known as BiondVax Pharmaceuticals Ltd is an Israel-based biopharmaceutical company that is principally focused on developing, manufacturing, and commercializing medical products for the prevention and treatment of autoimmune and infectious diseases but also for other illnesses. The Company’s core focus is to develop NanoAbs for the treatment of various diseases such as COVID-19, psoriasis, and asthma. The Company's product NanoAb is based on alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies. Additionally, the Company offers manufacturing facilities, aseptic fill and finish suites, laboratories, and experienced professionals for other research and development companies. Scinai Immunotherapeutics Ltd operates in Israel.

What is the price predicton of SCNI Stock?

Wall Street analysts forecast SCNI stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for SCNI is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Scinai Immunotherapeutics Ltd (SCNI)'s revenue for the last quarter?

Scinai Immunotherapeutics Ltd revenue for the last quarter amounts to 206.00K USD, decreased % YoY.

What is Scinai Immunotherapeutics Ltd (SCNI)'s earnings per share (EPS) for the last quarter?

Scinai Immunotherapeutics Ltd. EPS for the last quarter amounts to -0.00 USD, decreased -100.00 % YoY.

What changes have occurred in the market's expectations for Scinai Immunotherapeutics Ltd (SCNI)'s fundamentals?

The market is revising No Change the revenue expectations for SCNI for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -48.52%.

How many employees does Scinai Immunotherapeutics Ltd (SCNI). have?

Scinai Immunotherapeutics Ltd (SCNI) has 31 emplpoyees as of January 10 2026.

What is Scinai Immunotherapeutics Ltd (SCNI) market cap?

Today SCNI has the market capitalization of 2.64M USD.